Nu-Med Plus (NUMD) Liabilities and Shareholders Equity (2011 - 2025)

Nu-Med Plus has disclosed Liabilities and Shareholders Equity across 15 years of filings, most recently posting $7911.0 for Q4 2025.

• Liabilities and Shareholders Equity for Q4 2025 came in at $7911.0, down 15.6% year-over-year; the trailing twelve-month figure through Dec 2025 was $26295.0 (down 27.5% YoY), and the FY2025 annual result was $7911.0, down 15.6% from the prior year.
• Liabilities and Shareholders Equity came in at $7911.0 for Q4 2025 at Nu-Med Plus, up from $5048.0 in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $285013.0 in Q1 2021 to a low of $3168.0 in Q3 2022.
• The 5-year median for Liabilities and Shareholders Equity is $10207.0 (2024), against an average of $36600.4.
• Across the five-year window, Liabilities and Shareholders Equity sank 97.22% in 2022 and surged 645.26% in 2023, its largest moves.
• Nu-Med Plus' Liabilities and Shareholders Equity stood at $22163.0 in 2021, then jumped by 258.91% to $79545.0 in 2022, then tumbled by 83.08% to $13456.0 in 2023, then tumbled by 30.34% to $9373.0 in 2024, then decreased by 15.6% to $7911.0 in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $7911.0 (Q4 2025), $5048.0 (Q3 2025), and $8163.0 (Q2 2025), per Business Quant data.